← 프로그램 목록
ADCPhase 2Recruiting

Gemtuzumab Ozogamicin

Pfizer

비교

Gemtuzumab Ozogamicin(Pfizer)은 Acute Myeloid Leukemia 표적 ADC로, Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 6.15. 차별점: unique toxicities related to the antigen target, linker, or payload that have limited their development.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 9일 (5일 전)PK/독성 2026년 7월 9일 (5일 전)

Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia

Recruiting

Technology

구조모아 · Calicheamicin enediyne

ADCs) represent an important therapeutic modality for the treat

that

linker, or payload that have limited their development

humanized IgG4 anti-CD33 monoclonal antibody conjugated to the cytotoxic derivative of calicheamicin

unique toxicities related to the antigen target, linker, or payload that have limited their development

Mechanism of Action

targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen

macrophage activation

payload that have limited their development

HER2-positive, HER2-low

resistance mechanisms, highlighting the need to develop strategies that increase cell sensitivity to this ADC

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 65건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 2 · Phase 2, Phase 3 · Phase 3
  • Status: Completed · Unknown status · No longer available
  • 주요 endpoint: Sepsis-related toxicity of antibody-drug conjugate. · Causality assessment of reported cardiovascular events according to the WHO system · Description of the type of sepsis-related toxicities depending on the category of ADC · Description of the drug-drug interactions associated with sepsis-related adverse events · Description of the population of patients having a sepsis-related adverse events
  • 핵심: The aim of this observational study is to describe treatment patterns and effectiveness outcomes in a sample of oncology…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Gemtuzumab Ozogamicin은 어떤 치료제인가요?
Gemtuzumab Ozogamicin(Pfizer)은 Acute Myeloid Leukemia 표적 ADC로, Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Gemtuzumab Ozogamicin의 임상 단계는?
Gemtuzumab Ozogamicin의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.